

CORONAVIRUS UPDATE – MARCH 11, 2020

Like the rest of the world, the global Piramal Pharma Solutions organization is affected by the impact of the Coronavirus (COVID-19). It's important for you, our customer, to understand what we are doing to cope with the challenges of this quickly-evolving situation, both within our organization and outside it.

Supply Chain

As the COVID-19 situation unfolded, we reviewed our contingency and mitigation plans and made enhancements to our supply chain program. To date, a number of mitigation plans have been activated, including: backwards integration in our own organization to support security of supply for RSMs and KSMs; daily tracking of critical material deliveries; covering current, short-term needs with multiple suppliers; actively scouting and developing a network of alternate supply sources in India with R&D support; communicating regularly with vendors to remain on top of the latest information regarding manufacturing, couriers and port traffic; and ensuring that Piramal's supplies are dispatched immediately as soon as local transportation resumes.

As virus transmission has accelerated outside of China, we are also evaluating geographic dual or multi-sourcing options more broadly than China. Our network will develop additional mitigation plans where appropriate so we're ready to deal with any supply chain disruptions wherever they might occur. Across all our global sites, these

supply chain protocols are in place to support your needs. We are confident that the Piramal Pharma Solutions supply chain is well prepared to adapt to current market conditions as needed.

Health & Safety

Nothing is more important to us than the health and safety of our employees and our customers. We are closely monitoring guidance issued by the World Health Organization, the US Centers for Disease Control and Prevention, Public Health England, Health Canada and the Government of India Ministry of Health & Family Welfare, and other governments around the world. Accordingly, we have made certain decisions that impact our day-to-day interactions with customers.

Our employees have been advised to limit travel to only those circumstances where it is essential. Wherever possible, meetings should be arranged electronically using Skype, WebEx, and similar digital meeting tools. Customer visits to our sites should also be limited to those deemed essential, and must be approved in advance by the Site Head. Any customers who are then authorized to visit our sites should make sure that such meetings are also sanctioned by their own organizations and that proper precautions are followed as recommended by the government agencies mentioned above. We appreciate your patience in supporting these preventative steps so we can reduce the risk of unplanned disruptions at our manufacturing locations.

As we have all heard over the past few weeks, practicing social distancing, frequently washing your hands, and trying to avoid touching your eyes, nose, and mouth are good precautionary steps.

We are currently in the midst of a global crisis and increased uncertainty. Given our role as partner to innovative biopharma companies such as yours which enable ground-breaking pharmaceuticals, we are optimistic that science, human ingenuity, and society will ultimately prevail. However, solutions will take time. In the intervening period, we anticipate uncertainties and challenges, both known and unknown. Rest assured that despite these challenges, the Piramal Pharma Solutions team is committed to open communication and we are doing everything we can to continue to support your needs in the safest and most effective ways possible.

Sincerely,

A handwritten signature in blue ink, appearing to read "Peter DeYoung", with a stylized flourish extending to the right.

Peter DeYoung

CEO, Piramal Global Pharma